ArticleGates open research2018
Developing new health technologies for neglected diseases: a pipeline portfolio review and cost model.
Article in Gates open research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 23 citations in OpenAlex.
- Advancing diagnostics for Chagas disease: key product characteristics and harmonized evaluation strategies - an expert meeting report.BMC infectious diseases · 2026Article
- Global vaccine development.Nature medicine · 2026Review
- Investing in a global pooled-funding mechanism for late-stage clinical trials of poverty-related and neglected diseases: an economic evaluation.BMJ global health · 2023Article
- Evolution of research funding for neglected tropical diseases in Brazil, 2004-2020.PLoS neglected tropical diseases · 2023Article
- Investing in late-stage clinical trials and manufacturing of product candidates for five major infectious diseases: a modelling study of the benefits and costs of investment in three middle-income countries.The Lancet. Global health · 2022Article
- Public Risk-Taking and Rewards During the COVID-19 Pandemic - A Case Study of Remdesivir in the Context of Global Health Equity.International journal of health policy and management · 2022Article
- Who funded the research behind the Oxford-AstraZeneca COVID-19 vaccine?BMJ global health · 2021Article
- Alkaloids in Contemporary Drug Discovery to Meet Global Disease Needs.Molecules (Basel, Switzerland) · 2021Review
- Non-commercial pharmaceutical R&D: what do neglected diseases suggest about costs and efficiency?F1000Research · 2021Observational
- SARS-CoV-2 vaccine development, access, and equity.The Journal of experimental medicine · 2020Article
- Development of a TB vaccine trial site in Africa and lessons from the Ebola experience.BMC public health · 2020Article
- Analysis of the health product pipeline for poverty-related and neglected diseases using the Portfolio-to-Impact (P2I) modeling tool.F1000Research · 2020Article
- Analysis of the Health Product Profile Directory - a new tool to inform priority-setting in global public health.Health research policy and systems · 2019Article
- Trends in global health financing.BMJ (Clinical research ed.) · 2019Article
- Pipeline analysis of a vaccine candidate portfolio for diseases of poverty using the Portfolio-To-Impact modelling tool.F1000Research · 2019Article
- Neglected tropical diseases and the sustainable development goals: an urgent call for action from the front line.BMJ global health · 2019Article
- Improving resource mobilisation for global health R&D: a role for coordination platforms?BMJ global health · 2019Article
- Funding global health product R&D: the Portfolio-To-Impact Model (P2I), a new tool for modelling the impact of different research portfolios.Gates open research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 6 institutions in 4 countries.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.